Biotech Values

[DewDiligence]

More on The Imperial FDA
(reposted from iVillage):

http://investorvillage.com/smbd.asp?mb=971&mn=233784&pt=msg&mid=6232064

››
Msg 233784
2/4/2008 5:15:08 PM
Author: DewDiligence
In response to msg 233769 by mj121983

>They need to discontinue FDA panels. They are certainly nothing more than a show.<

Regrettably, the use of panels will increase relative to past reviews because the FDA’s new guidelines call for a panel to be convened for any drug that’s a new chemical entity.


>What good are the panels if the FDA disregards such overwhelmingly positive votes?<

The panels’ value would seem to be in giving the FDA two opportunities to reject:

1) “We’re rejecting this drug because the advisory
panel recommended against approval at this time.”

or

2) “We’re rejecting this drug because we
felt like it. Take that, motherf*ckers!”

--
>this FDA administration has to go.<

It’s hard to imagine how any drug/biotech investors could disagree.
‹‹